ArticleCancer medicine2024

Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.

Niamh Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.